VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.

Affiliation

Department of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, 03756, United States; Immunext Corp., Lebanon, NH, United States. Electronic address: [Email]

Abstract

V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator with limited homology to other B7 family members. The constitutive expression of VISTA on both the myeloid and T lymphocyte lineages coupled to its important role in regulating innate and adaptive immune responses, qualifies VISTA to be a promising target for immunotherapeutic intervention. Studies have shown differential impact of agonistic and antagonistic targeting of VISTA, providing a unique landscape for influencing the outcome of cancer and inflammatory diseases.

Keywords

Agonist,Antagonist,Autoimmunity,Cancer immunotherapy,Immune checkpoint,VISTA,

OUR Recent Articles